Aarti Pharmalabs Limited (AARTIPHARM) - Total Liabilities
Based on the latest financial reports, Aarti Pharmalabs Limited (AARTIPHARM) has total liabilities worth Rs-19.90 Billion INR (≈ $-215.20 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check AARTIPHARM asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Aarti Pharmalabs Limited - Total Liabilities Trend (2020–2025)
This chart illustrates how Aarti Pharmalabs Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see AARTIPHARM asset base.
Aarti Pharmalabs Limited Competitors by Total Liabilities
The table below lists competitors of Aarti Pharmalabs Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Peapack-Gladstone Financial
NASDAQ:PGC
|
USA | $7.25 Billion |
|
Wushang Group Co Ltd
SHE:000501
|
China | CN¥20.09 Billion |
|
Lincoln Educational Services
NASDAQ:LINC
|
USA | $293.48 Million |
|
Zhang Jia Jie Tourism Group Co Ltd
SHE:000430
|
China | CN¥672.43 Million |
|
Qt Group Oyj
HE:QTCOM
|
Finland | €57.63 Million |
|
Lloyds Banking Group PLC
LSE:LLOY
|
UK | GBX891.83 Billion |
|
Fox Factory Holding Corp
NASDAQ:FOXF
|
USA | $1.02 Billion |
|
Newonder Special Electric Co.Ltd
SHE:301120
|
China | CN¥137.45 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Aarti Pharmalabs Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Aarti Pharmalabs Limited to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | N/A | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aarti Pharmalabs Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aarti Pharmalabs Limited (2020–2025)
The table below shows the annual total liabilities of Aarti Pharmalabs Limited from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs9.16 Billion ≈ $99.12 Million |
+11.08% |
| 2024-03-31 | Rs8.25 Billion ≈ $89.23 Million |
+20.35% |
| 2023-03-31 | Rs6.86 Billion ≈ $74.14 Million |
+4.91% |
| 2022-03-31 | Rs6.53 Billion ≈ $70.67 Million |
+2807768.13% |
| 2021-03-31 | Rs232.71K ≈ $2.52K |
+24.61% |
| 2020-03-31 | Rs186.75K ≈ $2.02K |
-- |
About Aarti Pharmalabs Limited
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous sys… Read more